Tony Zook compensation by year
NEOGENOMICS Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $601,539 |
| Bonus | $0 |
| Stock awards | $3,999,997 |
| Option awards | $3,998,235 |
| Non-equity incentive | $513,400 |
| Pension and deferred compensation | $0 |
| All other | $13,921 |
| Total | $9,127,092 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NEOGENOMICS INC DEF 14A filed April 6, 2026, accession 0001077183-26-000014, and prior-year filings. Open the filing on EDGAR.
How this page was built: the NEOGENOMICS INC filed document, accession 0001077183-26-000014. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2026.
Change-in-control & termination
estimated payments NEOGENOMICS discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and resignation for good reason | $1,700,000 | $5,920,297 | $22,305 | $8,492,602 |
| Change in control and involuntary termination | $1,700,000 | $5,920,297 | $22,305 | $8,492,602 |
| Involuntary termination without cause | $850,000 | $1,973,424 | $22,305 | $3,695,729 |
| Resignation for good reason, no change in control | $850,000 | $1,973,424 | $22,305 | $3,695,729 |
Per the Potential Payments Upon Termination or Change in Control table in NEOGENOMICS INC's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
NEOGENOMICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Tony Zook · this page | Director and Chief Executive Officer | $9,127,092 |
| Warren Stone | President and Chief Operating Officer | $5,068,830 |
| Jeffrey Sherman | Chief Financial Officer | $4,681,428 |
| Christopher Smith | Former Director and Former Chief Executive Officer | $4,045,937 |
| Melody Harris | Former Chief Operations Officer and President, Oncology Data Solutions | $3,692,445 |
| Alicia Olivo | Executive Vice President, General Counsel & Business Development | $3,049,999 |
| Gary Passman | Chief Culture Officer | $2,443,195 |
Board service
NEOGENOMICS board · FY2024–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $21,200 | — | — | $0 | $21,200 |
| FY2024 | $80,357 | $168,000 | $72,000 | $0 | $320,357 |
Each year as the company reported it in NEOGENOMICS's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: NEOGENOMICS pays directors a $50,000 cash retainer and $240,000 in equity. As stated in NEOGENOMICS's FY2025 proxy.
Committees
Innovation, Pipeline and Technology
The full NEOGENOMICS compensation record
free company briefThis page is one person within NEOGENOMICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the NEOGENOMICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order NEOGENOMICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NEOGENOMICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order NEO
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.